Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 7, 2008, Pages 709-718

  Boerma, Marjan ^a   Fu, Qiang ^b   Wang, Junru ^b   Loose, David S ^c   Bartolozzi, Alessandra ^d   Ellis, James L ^d   McGonigle, Sharon ^d   Paradise, Elsa ^d   Sweetnam, Paul ^d   Fink, Louis M ^e   Vozenin Brotons, Marie Catherine ^f   Hauer Jensen, Martin ^g  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d Surface Logix Inc   (United States)

^e NEVADA CANCER INSTITUTE   (United States)

^f INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^g CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Endothelial cells; Fibroblasts; Genome expression profiling; Hydroxymethylglutaryl coenzyme A reductase inhibitors; Rho kinase; Smooth muscle cells

Indexed keywords

ACTIN; ATORVASTATIN; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; MEVALONIC ACID; RHO KINASE INHIBITOR; SLX 2119; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

AMINO ACID SEQUENCE; CELL LINE; CELLS, CULTURED; ENDOTHELIAL CELLS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPTANOIC ACIDS; HUMANS; MICROARRAY ANALYSIS; MUSCLE, SMOOTH; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PYRROLES; RHO-ASSOCIATED KINASES;

EID: 55049134780     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32830b2891     Document Type: Article

References (36)

1. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005; 21:247-269.
2. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006; 6:1-14.
3. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4:387-398.
4. Moriyama T, Nagatoya K. The Rho-ROCK system as a new therapeutic target for preventing interstitial fibrosis. Drug News Perspect 2004; 17:29-34.
5. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25:1767-1775.
6. Sacco RL, Liao JK. Drug insight: statins and stroke. Nat Clin Pract Cardiovasc Med 2005; 2:576-584.
7. Ludwig S, Shen GX. Statins for diabetic cardiovascular complications. Curr Vasc Pharmacol 2006; 4:245-251.
8. Irwin BC, Gupta R, Kim K, Han S, Ben-Josef E, Axelrod B, et al. Calcium channel blockers may radiosensitize patients to radiation proctitis while statins, NSAIDs may radioprotect: a case-control study [abstract]. Gastroenterology 2006; 130:A460.
9. Wang J, Boerma M, Fu Q, Kulkarni A, Fink LM, Hauer-Jensen M. Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys 2007; 68:1483-1490.
10. Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathe D, et al. Pravastatin inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res 2007; 13:5331-5340.
11. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97:1232-1235.
12. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23:512-517.
13. Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, et al. Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 2006; 17:3105-3114.
14. Yoneda A, Multhaupt HA, Couchman JR. The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol 2005; 170:443-453.
15. Bourgier C, Haydont V, Milliat F, Francois A, Holler V, Lasser P, et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005; 54:336-343.
16. Kuhn K, Baker SC, Chudin E, Lieu MH, Oeser S, Bennett H, et al. A novel, high-performance random array platform for quantitative gene expression profiling. Genome Res 2004; 14:2347-2356.
17. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711-2719.
18. Boerma M, Burton GR Wang J, Fink LM, McGehee RE Jr, Hauer-Jensen M. Comparative expression profiling in primary and immortalized endothelial cells: changes in gene expression in response to hydroxy methylglutaryl-coenzyme A reductase inhibition. Blood Coagul Fibrinolysis 2006; 17:173-180.
19. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25:25-29.
20. Shi J, Wang J, Zheng H, Ling W, Joseph J, Li D, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003; 14:575-585.
21. Haydont V, Mathe D, Bourgier C, Abdelali J, Aigueperse J, Bourhis J, et al. Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005; 76:219-225.
22. Hermann M, Christensen H, Reubsaet JL. Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS. Anal Bioanal Chem 2005; 382:1242-1249.
23. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42:1141-1160.
24. Wiesbauer F, Kaun C, Zorn G, Maurer G, Huber K, Wojta J. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Br J Pharmacol 2002; 135:284-292.
25. Uchiba M, Okajima K, Murakami K, Johno M, Mohri M, Okabe H, et al. rhs-TM prevents ET-mduced increase in pulmonary vascular permeability through protein C activation. Am J Physiol 1997; 273:L889-L894.
26. Waugh JM, Li-Hawkins J, Yuksel E, Kuo MD, Cifra PN, Hitfiker PR, et al. Thrombomodulin overexpression to limit neointima formation. Circulation 2000; 102:332-337.
27. Eberlein M, Heusinger-Ribeiro J, Gopperi-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133:1172-1180.
28. McGillicuddy FC, O'Toole D, Hickey JA, Gallagher WM, Dawson KA, Keenan AK. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol 2006; 44:469-475.
29. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118:10-24.
30. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26:8-22.
31. Zheng H, Wang J, Koteliansky VE, Gotwals PJ, Hauer-Jensen M. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Gastroenterology 2000; 119:1286-1296.
32. Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol 2005; 32:290-300.
33. Gabrys D, Greco O, Patel G, Prise KM, Tozer GM, Kanthou C. Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability. Int J Radiat Oncol Biol Phys 2007; 69:1553-1562.
34. Van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, Lankelma J, Emeis JJ, van Hinsbergh V. Simvastatin improves disturbed endothelial barrier function. Circulation 2000; 102:2803-2809.
35. Harvey SA, Anderson SC, SundarRaj N. Downstream effects of ROCK signaling in cultured human corneal stromal cells: microarray analysis of gene expression. Invest Ophthalmol Vis Sci 2004; 45:2168-2176.
36. Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 2004; 11:62-72.